Amica Retiree Medical Trust Purchases 6,344 Shares of Lam Research Co. (NASDAQ:LRCX)

Amica Retiree Medical Trust grew its position in Lam Research Co. (NASDAQ:LRCX) by 819.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,118 shares of the semiconductor company’s stock after purchasing an additional 6,344 shares during the period. Amica Retiree Medical Trust’s holdings in Lam Research were worth $514,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Insight Wealth Partners LLC bought a new position in Lam Research during the third quarter worth about $202,000. B&L Asset Management LLC bought a new position in shares of Lam Research during the 3rd quarter valued at about $204,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Lam Research in the 3rd quarter valued at approximately $220,000. Virtus Investment Advisers Inc. acquired a new stake in Lam Research during the 3rd quarter worth approximately $245,000. Finally, Qsemble Capital Management LP acquired a new position in shares of Lam Research in the third quarter valued at approximately $267,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Insider Activity at Lam Research

In other Lam Research news, SVP Seshasayee Varadarajan sold 110,080 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $90.00, for a total transaction of $9,907,200.00. Following the completion of the sale, the senior vice president now directly owns 179,084 shares in the company, valued at approximately $16,117,560. This trade represents a 38.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.29% of the stock is currently owned by company insiders.

Lam Research Stock Performance

NASDAQ:LRCX opened at $76.14 on Thursday. The stock’s 50-day moving average is $79.75 and its 200-day moving average is $77.33. The stock has a market cap of $97.74 billion, a P/E ratio of 23.13, a price-to-earnings-growth ratio of 1.47 and a beta of 1.53. Lam Research Co. has a 1-year low of $68.87 and a 1-year high of $113.00. The company has a current ratio of 2.54, a quick ratio of 1.73 and a debt-to-equity ratio of 0.51.

Lam Research (NASDAQ:LRCX) last issued its quarterly earnings data on Wednesday, January 29th. The semiconductor company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.04. Lam Research had a net margin of 26.49% and a return on equity of 51.86%. Equities research analysts anticipate that Lam Research Co. will post 3.71 earnings per share for the current year.

Lam Research Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 9th. Stockholders of record on Wednesday, March 5th will be given a dividend of $0.23 per share. The ex-dividend date is Wednesday, March 5th. This represents a $0.92 dividend on an annualized basis and a dividend yield of 1.21%. Lam Research’s dividend payout ratio (DPR) is 27.96%.

Analyst Ratings Changes

A number of equities analysts have issued reports on LRCX shares. Sanford C. Bernstein upgraded Lam Research from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $85.00 to $91.00 in a report on Thursday, January 30th. Oppenheimer assumed coverage on Lam Research in a research report on Thursday, March 20th. They issued an “outperform” rating and a $95.00 target price on the stock. Mizuho upped their price target on Lam Research from $87.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, February 20th. KeyCorp upgraded shares of Lam Research from a “sector weight” rating to an “overweight” rating and set a $95.00 price objective on the stock in a report on Friday, January 17th. Finally, Wolfe Research cut shares of Lam Research from an “outperform” rating to a “peer perform” rating in a report on Wednesday, January 15th. Six analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.06.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.